Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biosecurity

    Plum Island Scientists Develop New FMD Vaccine

    By Global Biodefense StaffJuly 5, 2012
    Share
    Facebook LinkedIn Reddit Email

    Scientists at the Plum Island Animal Disease Center (PIADC) have developed a molecular vaccine against foot and mouth disease virus (FMD).  The new vaccine does not use live FMD virus for vaccine manufacture, allowing for differentiation between an infected animal from an inoculated animal using common diagnostic tests.

    Traditional vaccines containing live virus have made it difficult to determine whether an animal is actually infected, or has simply been exposed to the vaccine.  Without this clear differentiation, such animals would be prohibited from entering any country that is designated FMD free.

    The FMD viral structure includes genetic material surrounded by a coat of proteins called a capsid.  The new vaccine produces only the virus coat particles, which form empty viral capsids, and not the entire genome of the virus; thus it lacks the infectious viral nucleic acids.  When the vaccine is injected into the animal the resulting empty viral capsids trigger a protective immune response. (Source: DHS)

    While noting that this virus only protects against one strain of FMD, the researchers are confident this breakthrough will pave the way for developing better countermeasures against all strains of the highly contagious disease.  “This is the biggest news in FMD research in the last 50 years,” says PIADC Director Dr. Larry Barrett.  “It’s the first licensed FMD vaccine that can be manufactured on the U.S. mainland, and it supports a vaccinate-to-live strategy in FMD outbreak response.”

    The new vaccine, originally discovered by Dr. Marvin Grubman in the USDA Agricultural Research Service at PIADC, took seven years to develop and license.  Dr. Bruce Harper, Director of Science at PIADC and the manager over PIADC’s Targeted Advanced Development Branch, led the development team, who worked with industry partners GenVec Inc., a biopharmaceutical company in Gaithersburg, Maryland, and Antelope Valley Biologics, a Benchmark Biolabs affiliate in Lincoln, Nebraska.

    “The absence of the nucleic acids of the real virus allows us to differentiate between vaccinated and infected animals,” said Grubman.  “This is critical when determining that an animal is free of infection after an FMD outbreak.  Now it will no longer be necessary to destroy all the animals in a herd when just a few become infected.”

    The vaccine was last month granted conditional license for use in cattle by the USDA Animal and Plant Health Inspection Service (APHIS) Center for Veterinary Biologics.  Under the conditional license, the product may be distributed should the need for it arise, as authorized by federal emergency management officials within USDA.  APHIS issued the conditional license to Antelope Valley Bios, Inc., who manufactured the vaccine under a contract from GenVec.

    PIADC has entered into a cooperative research and development agreement with Merial, the animal health division of Sanofi, to evaluate the FMD vaccine production process.  GenVec has licensed to Merial the rights to develop and commercialize their proprietary vaccine technology for use against FMD.

    Agro-Defense DHS FMD Vaccine News
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleJ&J Tuberculosis Drug Submitted for FDA New Drug Application Approval
    Next Article Battelle Awarded Up to $102M for Biodefense Research

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Human BCG Challenge Model for Assessment of Tuberculosis Immunity

    December 2, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023

    Inflammatix Completes Development for Acute Infection and Sepsis Test System

    November 15, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.